An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and TB-500. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for broader availability to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how policymakers view custom-mixed peptide therapies, which have drawn growing interest from users seeking alternatives to traditional drugs. Investigators say peptide treatments could alter approaches to stubborn infections, though concerns about consistency persist. The committee's endorsement of four peptides paves the way for more widespread prescribing, even as watchdogs warn of long-term evidence. Sector observers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on particular peptide candidates.